Addendum: Unravelling actionable biology using transcriptomic data to integrate mitotic index and Ki-67 in the management of lung neuroendocrine tumors

Venkata S.K. Manem; Olga Sazonova; Andréanne Gagné; Michèle Orain; Babak Khoshkrood-Mansoori; Nathalie Gaudreault; Yohan Bossé; Philippe Joubert

doi:10.18632/oncotarget.28321

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Addendum:

Addendum: Unravelling actionable biology using transcriptomic data to integrate mitotic index and Ki-67 in the management of lung neuroendocrine tumors

PDF | How to cite

Oncotarget. 2022; 13:1302-1302. https://doi.org/10.18632/oncotarget.28321

Metrics: PDF 626 views | ?

Venkata S.K. Manem¹, Olga Sazonova¹, Andréanne Gagné¹, Michèle Orain¹, Babak Khoshkrood-Mansoori¹, Nathalie Gaudreault¹, Yohan Bossé^1,2 and Philippe Joubert^1,3

¹Quebec Heart and Lung Institute Research Center, Quebec City, QC G1V4G5, Canada
²Department of Molecular Medicine, Laval University, Quebec City, QC G1V4G5, Canada
³Department of Medical Biochemistry, Molecular Biology and Pathology, Laval University, Quebec City, QC G1V4G5, Canada

Published: December 06, 2022

Copyright: © 2022 Manem et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has an addendum: All human tissues were sourced from the IUCPQ Biobank, which includes only patients that have signed a consent form for research.

Original article: Oncotarget. 2021; 12:209–220. DOI: https://doi.org/10.18632/oncotarget.27874

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28321

Publication Alerts

Post-Publication Promotion

Publication Discount

Addendum:

Addendum: Unravelling actionable biology using transcriptomic data to integrate mitotic index and Ki-67 in the management of lung neuroendocrine tumors